Ophthalmic Drugs
•46 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (46)
| Company | Market Cap | Price |
|---|---|---|
|
ABBV
AbbVie Inc.
Allergan’s eye-care business segments (ophthalmic drugs) form part of AbbVie’s product line.
|
$385.15B |
$218.07
-4.44%
|
|
AMGN
Amgen Inc.
TEPEZZA is an ophthalmic drug targeting thyroid eye disease.
|
$160.47B |
$298.45
+2.21%
|
|
REGN
Regeneron Pharmaceuticals, Inc.
EYLEA and EYLEA HD are ophthalmic drug products for eye diseases.
|
$69.08B |
$651.52
-0.39%
|
|
ALC
Alcon Inc.
Alcon markets ophthalmic drugs and prescription eye drops like Tryptyr.
|
$36.55B |
$73.92
-0.46%
|
|
VTRS
Viatris Inc.
The company has an ophthalmic drugs eye-care pipeline (Oyster Point assets), indicating direct ophthalmic drug offerings.
|
$12.16B |
$10.36
|
|
KRYS
Krystal Biotech, Inc.
KB801 and related ocular programs are ophthalmic drug therapies, placing Krystal Biotech in ophthalmic drugs.
|
$5.71B |
$196.63
+3.99%
|
|
BLCO
Bausch + Lomb Corporation
Ophthalmic Drugs – direct development, licensing, and commercialization of eye-disease medications (e.g., MIEBO, XIIDRA).
|
$5.29B |
$14.94
-1.32%
|
|
GKOS
Glaukos Corporation
Glaukos markets ophthalmic drugs such as iDose TR and corneal health therapies (Photrexa, Epioxa), which are administered to treat eye conditions.
|
$5.03B |
$88.05
+0.28%
|
|
BLTE
Belite Bio, Inc
Lead product Tinlarebant is an ophthalmic drug targeting retinal diseases (STGD1/GA).
|
$3.09B |
$105.92
+7.97%
|
|
PBH
Prestige Consumer Healthcare Inc.
Clear Eyes is an ophthalmic over-the-counter product, fitting Ophthalmic Drugs.
|
$2.99B |
$60.59
+0.52%
|
|
TARS
Tarsus Pharmaceuticals, Inc.
XDEMVY is an FDA-approved ophthalmic drug and core commercial product for Demodex blepharitis.
|
$2.89B |
$68.83
-0.19%
|
|
APLS
Apellis Pharmaceuticals, Inc.
SYFOVRE is an ophthalmic drug (intravitreal) approved for geographic atrophy, representing a direct product Apellis sells.
|
$2.71B |
$21.46
+3.55%
|
|
BHC
Bausch Health Companies Inc.
Lumify and other ophthalmic drug products place Bausch Health in the Ophthalmic Drugs category.
|
$2.60B |
$7.03
+6.28%
|
|
ANIP
ANI Pharmaceuticals, Inc.
ANI's Rare Disease/Brands expansion includes ophthalmic therapies ILUVIEN and YUTIQ acquired via Alimera, marking Ophthalmic Drugs as a direct product category.
|
$1.96B |
$90.62
-1.42%
|
|
OCUL
Ocular Therapeutix, Inc.
AXPAXLI and related candidates involve ophthalmic drug delivery components (ophthalmic drugs).
|
$1.86B |
$11.65
-1.40%
|
|
BCRX
BioCryst Pharmaceuticals, Inc.
Avoralstat for diabetic macular edema indicates an ophthalmic drug development program within BioCryst's pipeline.
|
$1.53B |
$7.32
+0.97%
|
|
HROW
Harrow Health, Inc.
Direct ophthalmic drug products (VEVYE, IHEEZO, TRIESENCE, BYQLOVI) are core branded ophthalmic pharmaceuticals.
|
$1.39B |
$37.77
+0.55%
|
|
KOD
Kodiak Sciences Inc.
Kodiak is developing ophthalmic drugs (intravitreal biologics) for retinal diseases, making Ophthalmic Drugs a core product category.
|
$956.34M |
$18.18
-13.66%
|
|
EYPT
EyePoint Pharmaceuticals, Inc.
Lead asset is an ophthalmic drug (DURAVYU) targeting wet AMD and DME.
|
$900.75M |
$13.11
+7.37%
|
|
LENZ
LENZ Therapeutics, Inc.
VIZZ is an aceclidine-based eye drop marketed as an ophthalmic drug for presbyopia.
|
$836.50M |
$29.71
-2.46%
|
|
OCS
Oculis Holding AG
Direct ophthalmic drug products (OCS-01, OCS-02, OCS-05) are the core offerings: ophthalmic drugs.
|
$808.70M |
$19.22
-4.33%
|
|
MGTX
MeiraGTx Holdings plc
Pipeline includes ocular gene therapy candidates (AIPL1/LCA4) targeting eye diseases, implying ophthalmic drug focus.
|
$729.72M |
$9.07
+3.89%
|
|
RGNX
REGENXBIO Inc.
ABBV-RGX-314 targets retinal diseases (wet AMD, diabetic retinopathy).
|
$640.55M |
$12.76
-0.47%
|
|
FDMT
4D Molecular Therapeutics, Inc.
4D-150 targets ophthalmic diseases (wet AMD and DME), making ophthalmic drug therapy a core area.
|
$532.73M |
$11.52
+1.77%
|
|
OCGN
Ocugen, Inc.
Ocugen develops ophthalmic drugs and therapies for eye diseases including RP, Stargardt, geographic atrophy, DME/DR/wet AMD.
|
$455.57M |
$1.55
+4.73%
|
|
LCTX
Lineage Cell Therapeutics, Inc.
OpRegen targets dry AMD, an ophthalmic indication; the program places Lineage in ophthalmic therapeutics.
|
$438.44M |
$1.93
+4.62%
|
|
OMER
Omeros Corporation
OMIDRIA royalties relate to ophthalmic drug products, a direct ophthalmic drug category.
|
$429.48M |
$7.32
-2.66%
|
|
DSGN
Design Therapeutics, Inc.
DT-168 is an eye drop for Fuchs endothelial corneal dystrophy, categorized as Ophthalmic Drugs.
|
$380.35M |
$6.69
+2.45%
|
|
ANNX
Annexon, Inc.
ANX007 is an ophthalmic intravitreal therapy for geographic atrophy, aligning with Ophthalmic Drugs.
|
$346.70M |
$3.16
+7.85%
|
|
AURA
Aura Biosciences, Inc.
bel-sar is an ophthalmic cancer therapy targeting ocular tumors, aligning with ophthalmic drug products.
|
$308.15M |
$6.13
+0.90%
|
|
ALDX
Aldeyra Therapeutics, Inc.
Lead reproxalap for dry eye disease is an ophthalmic drug, representing a direct product in ophthalmology.
|
$303.67M |
$5.08
+0.99%
|
|
LFCR
Lifecore Biomedical, Inc.
Proprietary HA manufacturing supports ophthalmic (and orthopedic) applications, aligned with Lifecore's HA platform.
|
$266.21M |
$7.18
+1.13%
|
|
TRDA
Entrada Therapeutics, Inc.
Strategic focus on ocular disease programs supports the Ophthalmic Drugs category as a direct product area.
|
$263.78M |
$6.96
+0.87%
|
|
ABEO
Abeona Therapeutics Inc.
Preclinical ophthalmic gene therapy programs (Stargardt disease, X-linked retinoschisis, optic atrophy) suggest ophthalmic drug/gene therapy applications.
|
$246.06M |
$4.80
-5.41%
|
|
SLRN
Acelyrin, Inc.
Lonigutamab targets an ophthalmic condition (thyroid eye disease), placing the company in Ophthalmic Drugs.
|
$228.61M |
$2.27
|
|
APLT
Applied Therapeutics, Inc.
AT-003 aims for strong retinal penetrance for diabetic retinopathy, aligning with Ophthalmic Drugs category.
|
$162.81M |
$1.15
+1.77%
|
|
IRD
Opus Genetics, Inc.
Ophthalmic drug products including RYZUMVI (phentolamine ophthalmic solution) and legacy APX3330; direct ophthalmic therapeutics.
|
$137.22M |
$2.28
+15.74%
|
|
SRZN
Surrozen, Inc.
Direct ophthalmic drug development focusing on retinal diseases using Wnt-modulating antibodies.
|
$119.88M |
$14.00
+2.56%
|
|
ADVM
Adverum Biotechnologies, Inc.
Ixo-vec is aimed at treating an eye condition (wet AMD) with an ophthalmic drug modality.
|
$89.83M |
$4.30
+1.65%
|
|
ABVC
ABVC BioPharma, Inc.
ABV-2002 is a corneal storage solution, placing ABVC in ophthalmic drug products.
|
$46.97M |
$2.77
-1.77%
|
|
OTLK
Outlook Therapeutics, Inc.
ONS-5010/LYTENAVA is a regulatory-approved ophthalmic formulation of bevacizumab for intravitreal use.
|
$42.30M |
$1.27
+2.42%
|
|
CLSD
Clearside Biomedical, Inc.
CLS-AX and XIPERE are ophthalmic drugs/formulations delivered via the platform.
|
$21.08M |
$4.03
+6.90%
|
|
PVCT
Provectus Biopharmaceuticals, Inc.
VisiRose EyeCo focuses on ophthalmic topical RBS (PV-305) for infectious keratitis, an ophthalmic drug product.
|
$15.32M |
$0.07
|
|
KPRX
Kiora Pharmaceuticals, Inc.
Company's pipeline focuses on ophthalmic therapeutics (KIO-301, KIO-104) targeting retinal degenerative diseases and retinal inflammation, i.e., Ophthalmic Drugs.
|
$7.03M |
$2.23
-12.55%
|
|
SNOA
Sonoma Pharmaceuticals, Inc.
Eye care products, aligning with ophthalmic drug offerings.
|
$6.47M |
$3.92
-0.76%
|
|
KALA
KALA BIO, Inc.
KPI-012 targets ocular diseases (PCED), fitting Ophthalmic Drugs.
|
$5.03M |
$0.78
+3.22%
|
Loading company comparison...
Loading industry trends...
Loading research report...
